CD30+ lymphomatoid skin toxicity secondary to ipilimumab

Ipilimumab is a monoclonal antibody that works by blocking the receptor cytotoxic T-lymphocyte–associated antigen-4 to increase T-cell activation and proliferation.1 Although a morbilliform rash is a well-known dermatologic toxicity of ipilimumab, to the best of our knowledge, there are no reports of CD30+ lymphoid skin reactions from ipilimumab.1